


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 438997269 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/2/04

Signature: *Victoria Parker*

(Victoria Parker)

Docket No.: 62075CIP(51590)
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gavril W. Pasternak et al.

Application No.: 10/827,063

Confirmation No.: 2362

Filed: April 19, 2004

Art Unit: 1614

For: COMPOSITIONS AND METHODS FOR
REVERSAL OF DRUG RESISTANCE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62075CIP(51590). A duplicate copy of this paper is enclosed.

Dated:

Respectfully submitted,

By 
Amy M. Leahy
Registration No.: 47,739
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
(203) 975-7505
Attorney for Applicant



PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/827,063-Conf. #2362	
			Filing Date	April 19, 2004	
			First Named Inventor	Gavril W. Pasternak	
			Art Unit	1614	
			Examiner Name	Not Yet Assigned	
			Attorney Docket Number	62075CIP(51590)	
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,306,876-B1	10-23-2001	Carson et al.	
	AB	US-6,057,371	05-02-2000	Glennon	
	AC	US-5,993,777	11-30-1999	John et al.	
	AD	US-5,767,125	06-16-1998	Crain et al.	
	AE	US-5,580,750	12-03-1996	Doglia et al.	
	AF	US-5,403,574	04-04-1995	Piwnica-Worms	
	AG	US-5,236,714	08-17-1993	Lee et al.	
	AH	US-Re. 36,547	02-01-2000	Crain et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^d
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Bowen WD, et al (1997) Proceedings of the Eighty-Eighth Annual Meeting of the American Association for Cancer Research, Vol. 38.	
	CB	Bowen WD, Sigma receptors: recent advances and new clinical potentials, Pharmaceutica Acta Helvetiae 74(2-3) (2000) 211-218.	
	CC	Brent PJ, et al (1995) Eur. J. Pharmacol. 278(2): 151-60	
	CD	Callaghan R, et al (1993) J. Biol. Chem. 268(21): 16059-64	
	CE	Callaghan R, et al (1995) Biochim. Biophys. Acta 1236(1): 155-62	
	CF	Conseil et al, (2001) Biochemistry 40(8): 2564-71	
	CG	Fine et al, (1996) Oncologist 1(4): 261-268	
	CH	Garrigues et al, (2002) Proc. Natl. Acad. Sci. USA 99(16): 10347-52	
	CI	Georg A, et al (1991) J. Pharmacol. Exp. Ther. 259: 479-83	
	CJ	Hellewell SB, et al (1990) Brain Res. 527: 224-253	
	CK	Kramer et al, (1995) Br. J. Cancer 71(4): 670-5.	
	CL	Krishan et al., Synergistic effect of prochlorperazine and dipyrindamole on the cellular retention and cytotoxicity of doxorubicin, Clinical Cancer Research Vol. 6, 1508-1517, April 2000.	
	CM	Laredo et al, (1994) Blood 84(1): 229-37	
	CN	Largent BL, et al (1987) Mol. Pharmacol. 32(6): 772-84.	
	CO	Litman et al, (1997) Biochim. Biophys. Acta 136(2): 169-76	
	CP	Loo et al., The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy, The FASEB Journal Vol 13, 1724-1732, October 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/827,063-Conf. #2362
				Filing Date	April 19, 2004
				First Named Inventor	Gavril W. Pasternak
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	62075CIP(51590)

	CQ	Matsuo et al, (2001) J. Control Release 77(1-2):77-86	
	CR	Pan et al, (2001) Chin. Med. J. 114(9): 929-32	
	CS	Pearce et al. (1989) Proc. Natl. Acad. Sci. USA 86: 5128-32	
	CT	Romsicki et al, (2001) Biochemistry 40(23): 6937-47	
	CU	Ross, D.D. (2000) Leukemia 14: 467-473	
	CV	Scotto et al. (1986) Science 232(4751): 751-5	
	CW	Schinkel et al, (1991) Cancer Res. 51(10): 2628-35	
	CX	Shtil, A.A. (2001) Curr. Drug Targets 2(1): 57-77	
	CY	Sikic et al, (1997) Cancer Chemother. Pharmacol. 40 (Suppl.): S13-S19	
	CZ	Tan, et al. (2000) Curr. Opin. Oncol. 12(5): 450-8	
	CA1	Thiebaut F, et al J. Histochem. Cytochem. 37(2): 159-64	
	CB1	van Den Elsen et al, (1999) Proc. Natl. Acad. Sci. 96(24): 13679-84	
	CC1	Vilner BJ, et al (1995) Cancer Res. 55(2): 408-13	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--